Hematotoxicity testing is a well-established field, and HALO-Tox HT has demonstrated strong in vitro to in vivo concordance, as reported by Olaharski et al. (2009) in Toxicology Letters. Designed in line with the 3Rs, it provides accurate lympho-hematotoxicity data from early discovery through clinical development.



While HemoGenix® does not perform animal studies in-house, we collaborate with CROs to maximize the value of preclinical research. When animal results are unexpected or inconsistent, specialized in vitro stem cell assays can detect functional cellular effects that standard morphology-based tests may miss, helping clarify underlying mechanisms.

For more information or to request a quotation, contact us at (719) 264-6250 or screening@hemogenix.com.